Radiation therapy in the management of brain metastases from renal cell carcinoma.
Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality. More effective treatment approaches are needed. Traditionally, whole-brain radiotherapy has been used for palliation. With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes. This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes. Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed.
Doh
Lucius S
LS
Amato
Robert
R
Paulino
Arnold C
AC
Teh
Bin S
BS
D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000532:radiotherapy* / Q000556:secondary; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008665:Metalloporphyrins / Q000627:therapeutic use; D009362:Neoplasm Metastasis / Q000532:radiotherapy*; D018787:Radiation Oncology / Q000639:trends*; D011838:Radiation-Sensitizing Agents; D016634:Radiosurgery / Q000009:adverse effects; D000077204:Temozolomide
D008665:Metalloporphyrins; D011838:Radiation-Sensitizing Agents; C437683:motexafin gadolinium; D003606:Dacarbazine; D000077204:Temozolomide